Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423895 | 0.88 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423968 | 0.84 | JAK2 (0.35) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209255 | 0.82 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25271092 | 0.82 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423878 | 0.78 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209301 | 0.76 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423873 | 0.76 | JAK2 (0.46) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423904 | 0.75 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL23209340 | 0.75 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL25220733 | 0.75 | JAK2 (0.43) | JAK2JAK1TYK2JAK3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |